Acumen Pharmaceuticals Inc (ABOS) Stock AnalysisABOSStock AnalysisAcumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Acumen Pharmaceuticals Inc (ABOS) is a good buy right now due to its current price of $2.92, which is significantly lower than the analyst price target of $8, suggesting a potential upside of over 173%. Additionally, the company has shown a positive trend with a year-to-date change of +44.55%, and despite recent losses, it has reduced its Q2 net loss to $32.72 million from $40.95 million last year, indicating improved financial management. The main risk is the negative earnings per share (EPS) of -0.45 reported for Q2 2026, which reflects ongoing financial challenges.